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Abstract 26 
 27 
Background: Nutrition support is an essential component of care for a child undergoing bone marrow 28 
transplantation (BMT). Enteral nutrition (EN) is becoming increasingly recognised as having advantages 29 
over parenteral nutrition (PN) and recommended as first-line nutrition support. EN has traditionally been 30 
provided via nasogastric tube (NGT). Gastrostomies avoid certain complications associated with NGTs 31 
and could provide a preferential alternative. 32 
 33 
Aims: To compare nutritional and post-transplantation outcomes during admission, the primary outcome 34 
being PN use, between children who had a gastrostomy placed prophylactically prior to BMT versus 35 
those who had not. 36 
 37 
Methods: Electronic medical records of children transplanted between January 2014 and May 2018 38 
within a single-centre were retrospectively reviewed. Outcomes between the gastrostomy group (n = 39 
54) and non-gastrostomy group (n = 91) were compared.  40 
 41 
Results: Multivariate regression analyses showed children in the gastrostomy group were less likely to 42 
require PN (odds ratio (OR) 0.4; 95% confidence interval (CI) 0.2-0.9; P = 0.049), initiated PN later if 43 
required (hazard ratio 0.6; 95% CI 0.4-0.8; P = 0.005), more often received EN as first-line nutrition 44 
support (P <0.001) and more frequently required EN post-discharge (OR 2.4; 95% CI 1.1-5.4; P = 0.029). 45 
No differences were found between groups on length of admission, day 100 overall survival, incidence 46 
of graft-versus-host-disease, positive blood cultures and changes in weight or albumin during admission. 47 
 48 
Conclusions: Providing EN via gastrostomy is feasible in this population and may be more acceptable 49 
to older children than NGTs. Weighing up the potential benefits against the potential risks of prophylactic 50 
gastrostomy placement in these high-risk children is a challenging decision. Further research 51 
investigating safety, longer-term outcomes and family perceptions of gastrostomy feeding is required. 52 
 53 
Keywords: Paediatric; bone marrow transplantation; gastrostomy; parenteral nutrition; enteral nutrition; 54 
nutritional status. 55 
1. Introduction 56 
 57 
Bone marrow transplantation (BMT) has become a well-recognised treatment for malignant and 58 
non-malignant diseases in children [1]. The intensive conditioning regimens used may cause side-59 
effects including nausea, vomiting, diarrhoea, anorexia and mucositis [2]. The receipt of donor cells 60 
brings further complications of graft-versus-host-disease (GvHD) which adds to catabolic demands. On 61 
commencement of treatment patients experience deterioration in nutritional intake [3] and nutritional 62 
status [4], putting them at risk of malnutrition. Negative associations have been found between 63 
malnutrition and overall survival (OS), transplant-related mortality and relapse risk [5]. Consequently, 64 
nutrition support becomes essential during BMT [6], but there is no consensus on the optimal method 65 
for its delivery. 66 
Traditionally parenteral nutrition (PN) has been considered the method of choice in this 67 
population [7]. However, the evidence seems to be shifting towards a preference for enteral nutrition 68 
(EN) as first-line nutrition support, as recommended by American and European guidelines [8,9]. With 69 
the already high risks this population face, it seems prudent PN should only be used when necessary 70 
given its association with catheter related complications [10], gut mucosal atrophy and increased line 71 
infections [11]. Studies offering first-line EN vs. PN to paediatric BMT patients have reported positive 72 
outcomes including better overall survival, less acute GvHD (aGvHD), better platelet engraftment and 73 
shorter admissions [12,13]. Furthermore, EN can help maintain gastro-intestinal integrity and reduce 74 
potential bacterial translocation [14]. 75 
With studies having focused on comparing EN vs. PN, few have directly compared EN 76 
interventions. Most paediatric BMT studies have administered EN via nasogastric tubes (NGTs) 77 
[12,13,15-17]. NGTs can be placed relatively simply during admission without the need for general 78 
anaesthetic and removed as soon as a patient’s intake returns to sufficient levels. However, they are 79 
susceptible to complications including dislodgement with vomiting, discomfort with mucositis, epistaxis 80 
in thrombocytopaenia [14] and placement refusal, all of which meaning PN may need to be used 81 
prematurely, or by default.  82 
Gastrostomy feeding offers an alternative route of providing EN, but has not commonly been 83 
used in this population due to concerns of infectious complications with neutropenia or 84 
thrombocytopenia [18]. Whilst one small retrospective study found more infectious complications in 85 
children with gastrostomies placed for BMT compared to those placed for other purposes [19], others 86 
have demonstrated nutritional optimisation without significant complications in similarly high-risk 87 
oncology populations [20,21]. The prophylactic placement of gastrostomies before the development of 88 
mucositis, gastrointestinal toxicities and thrombocytopaenia, provides the potential for nutrition support 89 
to be commenced at the earliest indication and maintained for longer periods without the risk of tube 90 
dislodgment by vomiting or removal in severe mucositis. This could reduce the need or duration of PN 91 
and its associated complications, allow longer-term nutrition support beyond discharge and reduce 92 
admission length if time is not required re-establishing EN following PN. However, balancing these 93 
potential advantages against the potential complications of surgery for gastrostomy placement and site 94 
infections in this high-risk population [19], is a difficult clinical decision. 95 
Few studies have investigated gastrostomy feeding as an alternative method to NGTs of 96 
providing nutrition support in paediatric BMT. The primary objective of this study was to compare PN 97 
use between gastrostomy vs. non-gastrostomy fed children during admission for BMT. We 98 
hypothesised that gastrostomy fed children used less PN during admission. Secondary objectives were 99 
to compare further nutritional and post-transplantation outcomes including weight and albumin changes, 100 
incidence of aGvHD, positive blood cultures and day 100 OS, between these two groups.  101 
 102 
 103 
 104 
 105 
 106 
 107 
 108 
 109 
 110 
 111 
 112 
 113 
 114 
2. Materials and methods 115 
 116 
2.1. Patients 117 
 118 
This retrospective cohort study was conducted in the United Kingdom’s largest paediatric BMT 119 
centre, Great Ormond Street Children’s Hospital (GOSH). All consecutive NHS and private patients 120 
(<18 years) who received an allogenic BMT following reduced-intensity (RIC) or myeloablative (MAC) 121 
conditioning, admitted from January 2014 and discharged by May 2018, were included. A sample-size 122 
calculation was not undertaken, but a post-hoc power analysis was planned. The retrospective nature 123 
of this study was chosen to obtain a larger sample size than would have been achieved prospectively. 124 
The centre’s guidelines offer first-line EN to all children. During a pre-transplantation interview 125 
families are provided comprehensive information regarding nutrition support. During this interview 126 
families make an informed choice between an NGT to be placed during admission, or prophylactic 127 
gastrostomy placed prior to admission to pre-empt the anticipated insult to nutritional status. This study 128 
compared two groups; children with a gastrostomy in situ on admission formed the gastrostomy group, 129 
those without formed the non-gastrostomy group. Exceptions to these guidelines were those receiving 130 
cord blood transplants or with pre-existing gastro-intestinal diseases (such as inflammatory bowel 131 
disease), who received first-line PN, and children already established on EN pre-admission who 132 
continued their current modality. These children, alongside non-recipients of conditioning or nutrition 133 
support, those who had a previous BMT or recruited to another trial applying transplant procedures not 134 
used in routine practice, were excluded (Fig. 1).  135 
Patients, GOSHs BMT multi-disciplinary team and a national BMT dietitians group were consulted 136 
and contributed to the development of this study. Ethical and organisational approvals were obtained 137 
from City, University of London and GOSH, reference number 17BA42. 138 
 139 
2.2. Nutrition Support  140 
 141 
From admission, all children were encouraged to maintain their oral intake, as able, throughout 142 
the transplant process, including a low microbial diet from the BMT ward and bottle or breastfeeding for 143 
infants. The target of any individual, or combination of, oral intake and nutrition support interventions 144 
were to meet the child’s requirements according to their age, sex and weight, for energy based on the 145 
Scientific Advisory Committee on Nutrition (2011) recommendations [22], and remaining macro and 146 
micronutrients based on Department of Health (1991) dietary reference values [23]. Intakes were 147 
recorded daily by nurses on fluid balance charts. These were assessed by a dietitian a minimum of 148 
three times weekly, who then advised families on provision of nutrition support, in conjunction with the 149 
BMT multi-disciplinary team. 150 
EN and PN were initiated and provided according to the same guidelines in both groups. EN was 151 
initiated when oral intake of food or fluids became insufficient to meet nutritional requirements or weight 152 
began to reduce from admission. Children in the non-gastrostomy group had a 5-8 Fr polyurethane 153 
NGT placed, unless refused, when the initiation criteria were met. They were not placed systematically 154 
on a specific day during transplant. NGTs were promptly replaced if dislodged up to three times, if 155 
allowed by the patient. Children in the gastrostomy group received EN via percutaneous endoscopic 156 
gastrostomy (PEG), placed prophylactically in the weeks prior to admission. 157 
EN was provided using an age appropriate polymeric formula (1kcal/ml), overnight via a pump 158 
with the volume gradually increased to establish tolerance, aiming to provide 50-70% requirements 159 
within five days. Once oral intake ceased, pump feeds or boluses were introduced during the day, with 160 
hypercaloric formula (1.5kcal/ml) used, if necessary, to provide 100% requirements. In cases of 161 
digestive intolerance including diarrhoea, formulae were changed to hydrolysed protein (1-1.5kcal/ml) 162 
to aid absorption. Children initiated PN, and ceased EN, in cases of severe mucositis, gut GvHD, NGT 163 
refusal or EN intolerance such as intractable vomiting and/or diarrhoea, despite manipulation to the 164 
feeding regimen, formula and optimisation of anti-emetic and anti-diarrhoea therapies. PN solutions 165 
included standard and tailor made bags with vamin given continuously over 24 hours and lipid over 20 166 
hours. Following engraftment, EN was gradually re-introduced over five days and PN simultaneously 167 
titrated and eventually stopped. EN was discontinued when a child’s oral intake met 70% requirements.  168 
 169 
2.3. Transplantation procedure and supportive care 170 
 171 
All children received allogenic BMT for various malignant and non-malignant diseases, according 172 
to the modalities and standard protocols of GOSH. Children received RIC or MAC conditioning, GvHD 173 
prophylaxis of ciclosporin with or without short-course methotrexate, corticosteroid or mycophenolate 174 
mofetil and veno-occlusive disease (VOD) prophylaxis of intravenous vitamin K and ursodeoxycholic 175 
acid. Donors were preferentially matched sibling, followed by matched family or unrelated, then either 176 
mismatch unrelated or haploidentical. Stem cell sources were bone marrow or peripheral blood. 177 
Recipient and donor cytomegalovirus (CMV) status, sex mismatch (male recipient, female donor) and 178 
CD34+ cell doses were noted, factors known to influence outcomes after allogenic transplant [24,25]. 179 
Infection prevention included protective isolation in individual high efficiency particulate air filtered 180 
rooms, a low microbial diet, pasteurised bottle feeds and adherence to the unit’s antimicrobial 181 
prophylaxis policy. 182 
 183 
2.4. Data collection  184 
 185 
Every child who underwent BMT at GOSH during the study’s time-period was initially included 186 
from a database of BMT protocols and vetted according to the exclusion criteria (Fig. 1). Data was 187 
collected between January and May 2018 by retrospectively free-text searching electronic copies of 188 
patients’ BMT protocols, medical, nursing and dietetic discharge summaries and the hospital’s 189 
pathology system for blood results. These sources provided all the necessary demographic, transplant 190 
modalities and outcome data necessary to allow comprehensive group comparisons and identify any 191 
differences that could confound results. The protocols and discharge summaries for every child, 192 
regardless of group allocation, were written according to a set pro forma and consequently provided 193 
similar information. Outcomes were selected following a data collection pilot using these information 194 
sources in the early stages of the study. Potential outcomes with excessively missing data were 195 
excluded, including nutritional intakes from oral and EN, and issues relating to EN tolerance such as 196 
incidence of vomiting and diarrhoea. The following outcomes were therefore known to have complete 197 
and usable data which was extracted onto an Excel spreadsheet. 198 
 199 
 200 
 201 
 202 
 203 
 204 
2.5. Outcome definitions 205 
 206 
From admission to discharge, the following measures were recorded and compared between 207 
groups. 208 
Use of nutritional interventions; (a) percent requiring PN for any time-period; (b) number of days 209 
PN was provided; (c) days from admission PN was initiated and stopped; (d) percent receiving EN as 210 
first-line nutrition support; (e) percent maintained exclusively on EN with no PN requirement; (f) percent 211 
requiring EN post-discharge. 212 
Changes in nutritional status were also investigated. Weight was measured on admission and daily 213 
until discharge. Anthropometric measures were converted from raw to Z-scores, adjusted for age and 214 
gender, using the LMS method [26]. Outcomes included; (g) change in weight Z-score; (h) percent 215 
losing 10% weight, as 10% weight loss in three months after allogeneic BMT has been associated 216 
with increased risk of subsequent non-relapse mortality (NRM) [4]; (i) change in albumin (g/L) from 217 
admission to the lowest level during admission and discharge; (j) percent having at least one episode 218 
of hypoalbuminaemia 30g/L. 219 
Post-transplantation outcomes; (k) incidence of aGvHD, diagnosed on the presence of clinical 220 
symptoms and/or histology markers of skin, liver and gut, graded I-IV using the modified Glucksberg 221 
criteria [27]; (l) incidence of VOD, diagnosed using the modified Seattle criteria [28]; (m) length of 222 
admission, measured in days from day of transplant/graft (day 0) to discharge; (n) neutrophil 223 
engraftment, defined as the first of three consecutive days with a count 0.5 x 109/L [29]; (o) percent 224 
having at least one bacterial infection confirmed by blood culture; (p) percent admitted to intensive care; 225 
(q) OS and NRM at day 100, as strong markers of early BMT toxicity [30]. Biochemical analyses 226 
including full blood count, urea, creatinine, electrolytes, liver function tests and blood cultures were 227 
performed frequently throughout admission allowing theses post-transplantation outcomes to be 228 
reported. 229 
 230 
2.6. Statistics 231 
 232 
All statistical analyses were performed using SPSS Version 24 between June-July 2018. All tests 233 
were two-tailed and p<0.05 was considered statistically significant. There were no missing data as the 234 
outcomes were selected following a data collection pilot. Outcome assessors were not blinded to 235 
participants’ group allocation. 236 
Descriptive statistics for categorical variables were expressed as frequencies and percentages 237 
and continuous variables by mean and standard deviation if normally distributed, median and 238 
interquartile range if skewed. Distribution normality was checked using skewness scores (skewed >1), 239 
Shapiro-Wilk test and histograms.  240 
Baseline characteristics between groups were compared using chi-squared or Fisher’s exact test, 241 
when appropriate, for categorical variables, and independent samples t-test or Mann Whitney U-test, 242 
depending on the data’s distribution, for continuous variables. 243 
Outcomes between groups were compared using a hierarchical approach to various regression 244 
models to control for confounding factors. Confounders were identified through univariate analysis and 245 
only those significantly associated with the outcome (p<0.05) were included in the final model. The 246 
significant confounders were added to the final model in blocks starting with demographic variables in 247 
block one, clinical variables in block two and the variable of interest (group allocation) in block three. 248 
Binary outcomes (e.g. presence of VOD), were analysed using logistic regression, continuous 249 
outcomes (e.g. PN duration) using linear regression and time-to-event outcomes (e.g. time to PN 250 
initiation) using the Kaplan-Meier method and Cox regression, with cases censored if they did not 251 
experience the event of interest. Model fits were checked for multicollinearity and normality, linearity, 252 
outliers, influential cases and homoscedasticity via residual analysis. Changes in weight Z-score and 253 
albumin during admission were analysed using two-way (mixed) ANOVA. 254 
The same statistical methods were used to perform two pre-planned subgroup analyses. Firstly, 255 
comparing gastrostomy and non-gastrostomy groups for those that only received MAC. Secondly, 256 
patients maintained exclusively on EN vs. those that received EN and further PN (regardless of 257 
gastrostomy/non-gastrostomy group). These are similar groups investigated in other studies [12,13] 258 
 259 
 260 
 261 
 262 
 263 
 264 
3. Results 265 
 266 
3.1. Study population 267 
 268 
A total of 264 children were transplanted over the study’s inclusion period. Seventy-four were 269 
potentially eligible to form the gastrostomy group, 190 the non-gastrostomy group. After vetting 270 
according to the exclusion criteria, data from 145 patients were extracted and analysed: 54 (37%) 271 
formed the gastrostomy group, 91 (63%) the non-gastrostomy group (Fig. 1). A post-hoc sample size 272 
calculation using G*Power 3.1 based on the primary outcome PN requirement (binary outcome), 273 
showed the achieved power was 0.42, small-medium effect size [31]. 274 
 275 
Fig. 1. Flow diagram showing the vetting of potentially eligible patients according to the exclusion criteria to form 276 
the gastrostomy and non-gastrostomy groups. 277 
 278 
Initial characteristics of patients and their transplantation modalities are summarised in Table 279 
1. Both groups were well matched on most characteristics with the only significant difference between 280 
groups being the proportions for recipient CMV serology (p=0.046). The flow of nutrition support 281 
modalities used between admission and discharge is shown in Fig. 2. Nutritional and post-282 
transplantation outcomes are summarised in Table 2. 283 
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Table 1 
Patient’s characteristics and transplantation modalities. 
 All patients 
(n= 145) 
Gastrostomy 
group (n= 54) 
Non-gastrostomy 
group (n= 91) 
P value 
Age (years), mean  SD 5.7  4.1 6.3  3.7 5.4  4.3 0.226a 
Private patient, n (%) 20 (13.8) 4 (7.4) 16 (17.6) 0.133b 
Gender, Male/Female, n 91/54 34/20 57/34 1.0b 
Diagnosis, n (%)    0.217b 
       Non-malignant diseases                        89 (61.4) 37 (68.5) 52 (57.1)  
       Malignant diseases 56 (38.6) 17(31.5) 39 (42.9)  
Disease status at transplant, n (%)    0.292c 
       Stable 88 (60.7) 36 (66.7) 52 (57.1)  
       Partial remission 2 (1.4) 0 (0) 2 (2.2)  
       CR  6 (4.1) 1 (1.9) 5 (5.5)  
       CR 1 10 (6.9) 2 (3.7) 8 (8.8)  
       CR  2 32 (22.1) 14 (25.9) 18 (19.8)  
       Progressive disease 7 (4.8) 1 (1.9) 6 (6.6)  
Stem cell source, n (%)    0.715b 
        Bone marrow 99 (68.3) 38 (70.4) 61 (67.0)  
        Peripheral blood 46 (31.7) 16 (29.6) 30 (33.0)  
Donor, n (%)    0.550c 
        MSD 38 (26.2) 10 (18.5) 28 (30.8)  
        MFD 9 (6.2) 4 (7.4) 5 (5.5)  
        MUD 76 (52.4) 32 (59.3) 44 (48.4)  
        Haploidentical 7 (4.8) 3 (5.6) 4 (4.4)  
        MMUD 15 (10.3) 5 (9.3) 10 (11.0)  
Sex mismatch (male recipient, 
female donor), n (%) 
33 (22.8) 11 (20.4) 22 (24.2) 0.684b 
Recipient CMV serology, n (%)    0.046b 
       Positive 47 (32.4) 12 (22.2) 35 (38.5)  
       Negative 98 (67.6) 42 (77.8) 56 (61.5)  
Conditioning regimen, n (%)    0.864b 
        Myeloablative 82 (56.6) 30 (55.6) 52 (57.1)  
        Reduced-intensity 63 (43.4) 24 (44.4) 39 (42.9)  
Number of CD 34+ cells infused, 
mean  SD 
11.0  8.7 10.4  8.4 11.3  8.8 0.586a 
Anthropometric Z-scores, age and 
gender adjusted, mean  SD 
    
        Weight  -0.5  1.6 -0.4  1.7 -0.6  1.6 0.535a 
        Height -1.2  1.9 -1.1  1.7 -1.2  2.0 0.630a 
        BMI  0.3  1.7 0.3  1.8 0.3  1.6 0.827a 
Abbreviations: CMV, cytomegalovirus; CR, complete remission; IQR, interquartile range [25%-75%]; MFD, matched 
family donor; MMUD, mismatched unrelated donor; MSD, matched sibling donor; MUD, matched unrelated donor; 
SD, standard deviation. 
a Comparison using independent samples t-test. 
b Comparison using Fisher’s exact test. 
c Comparison using Chi-square test. 
 344 
 345 
Fig.2. Flow of nutrition support modalities provided between admission and discharge. 346 
a Gastrostomies placed prophylactically a median [IQR], 22 [15.8-37.3] days pre-graft.  347 
b NGTs placed a median [IQR], day -3 pre-graft, [day -7.5 pre-graft to day 1.5 post-graft].  348 
c Gastrostomies placed a median [IQR], 56 [44-92] days post-graft. 349 
d Percentages calculated excluding deaths. 350 
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Table 2 
Nutritional and post-transplantation outcomes. 
 All patients 
(n= 145) 
Gastrostomy 
group (n= 54) 
Non-
Gastrostomy 
group (n= 91) 
P value 
PN     
   PN requirement, n (%) 111 (76.6) 37 (68.5) 74 (81.3) 0.049a 
   Days PN providedg, median [IQR] 31 [20.0-57.0] 31 [22.0-53.0] 31 [18.0-61.3] 0.140b 
   Day PN initiated from admission, median [IQR] 16 [11.0-38.0] 21 [13.0-94.0] 13 [10.0-25.0] 0.005c 
   Day PN stopped from admission, median [IQR] 52 [39.0-80.0] 52 [39.0-82.0] 51 [37.0-79.0] 0.312c 
EN     
   EN provided as first-line nutrition support, 
   n (%) 
126 (86.9) 54 (100) 72 (79.1) <0.001d 
   Maintained on EN only, n (%) 34 (23.4) 17 (31.5) 17 (18.7) 0.049a 
   Received EN and further PN, n (%) 96 (66.2) 37 (68.5) 59 (64.8) 0.718d 
   Discharged requiring enteral feedsh, n (%) 82 (59.9%) 36 (69.2) 46 (54.1) 0.029a 
Weight     
   Admission weight Z-score, mean  SD -0.5  1.6 -0.4  1.7 -0.6  1.6  See 
section 
3.3.e    Discharge weight Z-score, mean  SD -0.5  1.5 -0.4  1.6 -0.7  1.5 
    10% weight loss during admission, n (%) 8 (5.5) 1 (1.9) 7 (7.7) 0.258d 
Albumin     
   Admission, g/L, mean  SD 38.7  4.60 38.1  4.1 39.0  4.9 
See 
section 
3.3.e 
   Lowest albumin during admission, g/L, 
   mean  SD 
26.6  3.4 26.8  2.8 26.4  3.8 
   Discharge, g/L mean  SD 35.02  4.6 34.8  3.9 35.1  5.0 
   Hypoalbuminaemia  30g/L during admission, 
    n (%) 
125 (86.2) 48 (88.9) 77 (84.6) 0.620d 
aGvHD     
   Grade I-II, n (%) 62 (42.8) 25 (46.3) 37 (40.7) 0.448a 
   Grade III-IV, n (%) 8 (5.5) 2 (3.7) 6 (6.6) 0.664a 
   Gut aGvHD, n (%) 11 (7.6) 2 (3.7) 9 (9.9) 0.191a 
Veno-occlusive disease, n (%) 10 (6.9) 4 (7.4) 6 (6.6) 0.658a 
Length of admission (day 0 to discharge),  
   median [IQR] 
46 [36-76] 45 [36-66] 46 [36-80] 0.625c 
Days to neutrophil engraftment, mean  SD 20.4  6.0 20.8  6.1 20.2  6.0 0.877c 
 one positive blood culture for bacteria, 
   n (%) 
24 (16.6) 8 (14.8) 16 (17.6) 0.665d 
Admission to intensive care, n (%) 15 (10.3) 4 (7.4) 11 (12.1) 0.416d 
Mortality at day 100i     
   All causes, n (%) 5 (3.5) 0 5 (5.5) 0.081f 
   NRM, n (%) 4 (2.8) 0 4 (4.4) 0.120f 
Abbreviations: aGvHD, acute graft versus host disease; EN, enteral nutrition; day 0, day of transplantation; IQR, 
interquartile range [25%-75%]; NRM, non-relapse mortality; PN, parenteral nutrition; SD, standard deviation. 
a Comparison using logistic regression.   
b Comparison using linear regression, weighted least squares. 
c Comparison using Cox regression. 
d Comparison using Fisher’s exact test. 
e Comparison using two-way (mixed) ANOVA. 
f  Comparison using Kaplan-Meier method, log rank statistic.  
g Excluding non-recipients of PN (n=34). 
h Excluding deaths during admission (n=8). 
i  Four died during admission but post day 100. One died between discharge and day 100. 
3.2. Nutrition support interventions 405 
 406 
Children in the gastrostomy vs. non-gastrostomy group more often received first-line EN (p<0.001), 407 
due to NGT refusal in 20.9% of the non-gastrostomy group (Fig. 2, Table 2).   408 
The original odds of receiving PN in the gastrostomy group were 2.18 and in the non-gastrostomy 409 
group 4.35 (OR 0.50). After controlling for age, diagnosis and conditioning, those in the gastrostomy 410 
group become significantly less likely to require PN (OR 0.42, p=0.049, 95% CI 0.18-0.99) (Table 3A). 411 
Rationale for PN included gut aGvHD (n=11), refusal of NGTs in the non-gastrostomy group (n=19), 412 
and various transplant related complications, mucositis and intolerance symptoms including vomiting 413 
and diarrhoea, which could not be accurately quantified retrospectively, for the remaining 81 children. 414 
Time from admission to PN initiation was significantly delayed in the gastrostomy group (HR 0.56, 415 
p=0.005, 95% CI 0.37-0.84), after controlling for age, private patients and diagnosis (Table 4A, Fig. 5A). 416 
PN duration was no different between groups (p=0.140, 95% CI -12.46-1.78), after controlling for gender 417 
and donor (Table 5). Time to PN cessation was no different between groups (gastrostomy group HR 418 
0.88, p=0.558, 95% CI 0.58-1.34), after controlling for donor (Table 4B, Fig. 5B).  419 
The original odds of requiring EN post-discharge in the gastrostomy group were 2.25 and in the 420 
non-gastrostomy group 1.18 (OR 1.9). After controlling for age, those in the gastrostomy group were 421 
more likely to be discharged requiring EN (OR 2.41, p=0.029, 95% CI 1.09-5.38) (Table 3B). Seven in 422 
the non-gastrostomy group required gastrostomy placement for feeds (n=4) or fluids/meds (n=3) prior 423 
to discharge, having previously refused NGT (n=4), or failing with NGT feeds (n=3) (Fig. 2).  424 
Gastrostomy vs. non-gastrostomy MAC subgroup analysis was consistent with the above results 425 
showing no differences in use of nutrition support interventions, except PN requirement which was not 426 
different between groups (gastrostomy group OR 0.51, p=0.258, 95% CI 0.16-1.63). 427 
 428 
3.3. Nutritional status 429 
 430 
No difference was found between groups of 10% weight loss (p=0.258). Mean (SD) weight Z-431 
score remained approximately stable during hospitalisation in both groups, with non-significant main 432 
effects for time (p=0.972), interaction (p=0.244), and group (p=0.379) (Fig. 4A). The same pattern was 433 
found in the subgroups comparing those maintained exclusively on EN vs. EN+PN and those that 434 
received MAC between the gastrostomy and non-gastrostomy groups. However, in the latter subgroup, 435 
despite there being a non-significant main effect for time (p=0.862), and interaction (p=0.584), there 436 
was a significant effect between groups (p=0.028) (Fig. 4B).  437 
Between groups, no difference was found in hypoalbuminaemia (p=0.620), or the lowest albumin 438 
during admission (p=0.447, 95% CI -0.67-1.51). Throughout hospitalisation there were non-significant 439 
main effects between groups (p=0.666), and interaction (p=0.257), but a significant effect for time 440 
(p<0.001) (Fig. 4C). The same pattern was found for both subgroups. 441 
 442 
                            443 
Fig. 4. Changes during hospitalisation between gastrostomy (dotted line) and non-gastrostomy (plain line) groups 444 
in mean weight Z-score (A), mean weight Z-score for the MAC subgroup (B) and serum albumin (C). 445 
 446 
3.4. Post-transplantation outcomes 447 
 448 
Comparing groups, no differences were found in any of the post-transplantation outcomes defined 449 
in section 2.5. (Table 2).  450 
The original odds of developing grade I-II aGvHD were 0.86 in the gastrostomy and 0.69 in the 451 
non-gastrostomy group (OR 1.25). After controlling for diagnosis, conditioning and stem cell source, 452 
group allocation was not significantly associated with grade I-II aGvHD (OR 1.32, p=0.448, 95% CI 453 
0.65-2.67) (Table 3C). The original odds of developing grade III-IV aGvHD were 0.04 in the gastrostomy 454 
and 0.07 in the non-gastrostomy group (OR 0.57). After controlling for diagnosis, group allocation was 455 
not significantly associated with grade III-IV aGvHD (OR 0.69, p=0.664, 95% CI 0.13-3.71) (Table 3D). 456 
The original odds of developing gut aGvHD were 0.04 in the gastrostomy and 0.11 in the non-457 
gastrostomy group (OR 0.36). No predictors were univariately significantly associated with gut aGvHD, 458 
so only group was included in the model which was non-significant (OR 0.35, p=0.191, 95% CI 0.07-459 
1.69) (Table 3E). 460 
The original odds of developing VOD were 0.08 in the gastrostomy and 0.07 in the non-461 
gastrostomy group (OR 1.14). After controlling for diagnosis, group allocation was not significantly 462 
associated with VOD (OR 1.36, p=0.658, 95% CI 0.35-5.21) (Table 3F). 463 
Regarding length of admission, after controlling for donor, no difference between groups was found 464 
(gastrostomy group HR 1.09, p=0.625, 95% CI 0.77-1.55) (Table 4C, Fig. 5C).  465 
Time to neutrophil engraftment, after controlling for private patients, infused CD34+ cells, stem 466 
cell source and conditioning, was no different between groups (gastrostomy group HR 0.97, p=0.877, 467 
95% CI 0.68-1.38) (Table 4D, Fig. 5E).  468 
Day 100 OS was also no different between gastrostomy vs. non-gastrostomy groups (100% vs. 469 
94.5%, p=0.081) (Fig.5F). 470 
The only significant differences found in subgroup analyses were, compared to the EN+PN group, 471 
the EN only group had fewer admissions to intensive care (0% vs. 15%, p=0.020), and a shorter 472 
admission (EN group HR 3.57, p<0.001, 95% CI 2.29-5.57). (Table 4E, Fig. 5D). 473 
Additional subgroup analysis comparing the 19 children who refused NGTs and received first-line 474 
PN to the 126 who received first-line EN, showed those who refused NGTs were older, mean (SD), 9.3 475 
(4.0) vs. 5.2 (3.9), (p<0.001, 95% CI -6.02 to -2.23), but had no significant differences in any post-476 
transplantation outcomes. Interestingly, those that refused NGTs had a longer admission (median [IQR], 477 
63 [39-89] vs. 45 [36-73] days), but this was not significant (Kaplan-Meier log rank statistic p=0.284). 478 
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Table 3 
Coefficients of the final logistic regression models comparing gastrostomy vs. non-gastrostomy groups. 
 
b 
Standard 
error 
P 
value 
OR 
95% CI 
Lower Upper 
A Model (block three) predicting PN use. 
        Constant 0.81 0.50 0.105 2.26   
        Age 0.16 0.06 0.011 1.18 1.04 1.34 
        Malignant diseasesa 0.68 0.63 0.286 1.96 0.57 6.79 
        RICb -0.59 0.53 0.267 0.55 0.19 1.57 
        Gastrostomy groupc -0.87 0.44 0.049 0.42 0.18 0.99 
 
B Model (block two) predicting EN requirements post-discharge. 
        Constant 1.30 0.36 <0.001 3.66   
        Age -0.21 0.05 <0.001 0.81 0.73 0.90 
        Gastrostomy groupc 0.89 0.41 0.029 2.41 1.09 5.38 
 
C Model (block two) predicting grade I-II aGvHD. 
        Constant -0.48 0.56 0.394 0.62   
        Malignant diseasesa 0.26 0.0.45 0.565 1.30 0.53 3.16 
        RICb -0.62 0.49 0.205 0.54 0.20 1.41 
        Bone marrowd 0.34 0.44 0.436 1.41 0.60 3.33 
        Gastrostomy groupc 0.27 0.36 0.448 1.32 0.65 2.67 
 
D Model (block two) predicting grade III-IV aGvHD. 
        Constant -4.34 1.05 <0.001 0.01   
        Malignant diseasesa 2.50 1.09 0.022 12.12 1.44 101.96 
        Gastrostomy groupc -0.37 0.86 0.664 0.69 0.13 3.71 
 
E Model (block one) predicting gut aGvHD. 
        Constant -2.21 0.35 <0.001 0.11   
        Gastrostomy groupc -1.05 0.80 0.191 0.35 0.07 1.69 
 
F Model (block two) predicting VOD. 
        Constant -3.49 0.68 <0.001 0.03   
        Malignant diseasesa 1.45 0.72 0.044 4.25 1.04 17.40 
        Gastrostomy groupc 0.30 0.69 0.658 1.36 0.35 5.21 
 
Baseline: anon-malignant diseases, bMAC, cnon-gastrostomy group, dperipheral blood. 
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Table 4 
Coefficients of the final Cox regression models between gastrostomy vs. non-gastrostomy groups (and E 
comparing EN only vs. EN+PN subgroup). 
 
b 
Standard 
error 
P 
value 
HR 
95% CI 
Lower Upper 
A Model (block three) predicting time to PN initiation. 
        Age 0.07 0.03 0.007 1.07 1.02 1.12 
        NHS patienta -0.50 0.27 0.063 0.61 0.36 1.03 
        Malignant diseasesb 0.70 0.20 0.001 2.01 1.36 2.99 
        Gastrostomy groupc -0.59 0.21 0.005 0.56 0.37 0.84 
 
B Model (block two) predicting time to PN cessation. 
        Related donor (any type)d 0.51 0.21 0.013 1.67 1.11 2.50 
        Gastrostomy groupc -0.12 0.21 0.558 0.88 0.58 1.34 
 
C Model (block two) predicting time to discharge. 
        Related donor (any type)d 0.39 0.18 0.033 1.47 1.03 2.09 
        Gastrostomy groupc 0.09 0.18 0.625 1.09 0.77 1.55 
 
D Model (block three) predicting time to neutrophil engraftment. 
        NHS patienta -0.69 0.26 0.007 0.50 0.30 0.83 
        Infused CD34+ cells 0.02 0.01 0.183 1.02 0.99 1.04 
        Bone marrowf -1.03 0.27 <0.001 0.36 0.21 0.60 
        RICg -0.01 0.21 0.949 0.99 0.65 1.49 
        Gastrostomy groupc -0.03 0.18 0.877 0.97 0.68 1.38 
 
E Model (block one) predicting time to discharge. 
        EN only subgroupe 1.27 0.23 <0.001 3.57 2.29 5.57 
 
Baseline: aprivate patient, bnon-malignant diseases, cnon-gastrostomy group, dunrelated donor (any type), 
eEN+PN subgroup, fperipheral blood, gMAC. 
Table 5 
Coefficients of the final multiple linear regression model (block three) using weighted least squares, 
predicting PN duration between gastrostomy and non-gastrostomy groups. 
 
b Standard error P value 
95% CI 
Lower Upper 
    Constant 22.10 3.50 <0.001 15.17 29.03 
    Femalesa 8.64 5.00 0.085 -1.21 18.49 
    Related donor (any type)b -4.60 3.63 0.208 -11.79 2.59 
    Gastrostomy group* -5.34 3.59 0.140 -12.46 1.78 
Baseline: amales, bunrelated donor (any type). 
 569 
Fig. 5. Cumulative incidence between gastrostomy (dotted line) and non-gastrostomy (plain line) groups of PN 570 
initiation (censored: 34 who did not receive PN) (A), PN cessation (censored: 34 who did not receive PN, two 571 
discharged on PN, eight deaths whilst receiving PN) (B), discharge (censored: eight deaths during admission) (C), 572 
discharge between subgroup receiving EN only (dotted line) and EN+PN (plain line) (censored: eight deaths during 573 
admission) (D), neutrophil engraftment (no censored cases) (E), estimated probability of day 100 overall survival 574 
(censored: 141 who did not die) (F). 575 
 576 
 577 
4. Discussion 578 
 579 
To our knowledge, this is the second largest cohort investigating nutrition support, and the first 580 
regarding prophylactic gastrostomy feeding, in paediatric BMT. Children with a prophylactic 581 
gastrostomy were more likely to receive first-line EN, be maintained exclusively on EN without requiring 582 
additional PN, initiate PN later if required, and be discharged requiring EN, whilst experiencing similar 583 
post-transplantation outcomes and weight and albumin changes during admission. 584 
European adult guidelines recommend first-line EN in BMT [9]. Whilst no equivalent guidelines 585 
exist in paediatrics, a recent Cochrane review concluded there is limited evidence to suggest PN is 586 
more effective than EN [32]. Paediatric studies are also increasingly recommending first-line EN during 587 
BMT [12,13]. Despite every child in this study having the opportunity to receive first-line EN, this 588 
approach occurred more frequently in the gastrostomy group. Whilst families who opted for gastrostomy 589 
possibly have a more proactive approach to EN, NGT refusal was the reason PN was provided first-590 
line in 21% of the non-gastrostomy group. This issue has been reported elsewhere to lesser extents 3-591 
4% [12,13,17]. These children did not develop more post-transplant complications so received first-line 592 
PN inappropriately when they were well enough to receive first-line EN, with additional PN only when 593 
appropriate. They were also older, similar findings to other studies [17,33]. Aesthetics or trauma of NGT 594 
placement could explain refusal amongst this group, issues likely absent in younger children. Indeed, 595 
displeasure of NGT placement and preference for PN with pre-existing IV access has been reported in 596 
paediatric oncology [34]. The positioning of a gastrostomy tube could provide a more acceptable 597 
method of providing EN to older children and avoid inappropriate PN use. 598 
Overall, 77% required PN, higher than 10-30% reported in similar studies [15-17,35], and some 599 
only studied those receiving MAC [12,13]. This high PN use could be explained by the current absence, 600 
and need for implementation, of a nutrition support protocol in our unit. Such pathways help guide the 601 
decision making of clinicians ensuring appropriate use of nutrition support, and have been shown to 602 
reduce PN use [36]. Children in the gastrostomy group were significantly less likely to require PN, and 603 
initiated it later if required. Although PN initiation was measured from admission, if accounting for seven 604 
days of conditioning, the non-gastrostomy group initiated PN day six post-graft, earlier in comparison 605 
to 11-14.5 days [12,13,16], which are more comparable to the gastrostomy group who initiated PN 14 606 
days’ post-graft. Despite the gastrostomy group initiating PN later, duration was similar, 31 days, 607 
between groups. Duration ranges widely in the literature from eight [15], to 54 days [33]. Gastrostomies 608 
avoid risks associated with NGTs including dislodgement through vomiting, placement contraindication 609 
in thrombocytopaenia and pain with mucositis [14]. Coupling these issues with NGT refusal, means 610 
they could lead to premature and inappropriate use of PN when it would otherwise be clinically 611 
preferable to initiate and maintain EN throughout transplant. Other researchers have advocated the 612 
systematic placement of NGTs day one post-graft to overcome these issues [12]. In this study NGTs 613 
were placed sooner, on average three days’ pre-graft. Although we could not capture the issues that 614 
arose with NGTs, perhaps coupling these with NGT refusals, led to greater and earlier need for PN. 615 
Alternatively, the high percentage of NGT refusals and earlier PN initiation in the non-gastrostomy group 616 
could highlight a lack of perseverance with NGTs and need for a more stringent approach towards their 617 
placement and initiation and maintenance of EN via this route. 618 
Significantly more children in the gastrostomy (69%) than non-gastrostomy group (54%) required 619 
EN post-discharge, proportions higher than 45% [15] and 47% [16]. Eating difficulties and poor 620 
compliance with dietary advice post-discharge have been reported [37], and significant correlations 621 
have been found between duration of EN and improvement in weight [35]. These results could reflect 622 
our proactive EN approach to support intakes and weight gain post-discharge. We note one study 623 
amended their protocol to continue EN post-discharge following BMI reductions during admission with 624 
limited regain three months’ post-graft in their EN group [13]. The between group differences could be 625 
explained by the NGT refusals in the non-gastrostomy group and NGT policy in the community which 626 
forbids overnight feeding due to risks of tube dislodgement and feed aspiration, whereas overnight 627 
gastrostomy feeding is routinely used. For NGTs the child is therefore limited to having day time feeds 628 
which may be stopped prematurely in preference for progression of oral intake. Interestingly, seven 629 
children who had not opted for prophylactic gastrostomy required one to provide feeds, fluids and/or 630 
medicines for discharge, and perhaps would have benefitted from placement pre-admission. 631 
Regarding nutritional status, weight was approximately maintained for all children between 632 
admission and discharge. Overall, 5.5% lost 10% weight, comparable to 8% [12]. Other studies have 633 
also shown anthropometric maintenance throughout admission, but using mid-upper-arm 634 
circumference (MUAC) and triceps skinfold thickness [33,35]. In keeping with other studies, we have 635 
shown hypoalbuminaemia to be common following BMT, although the 86% experiencing levels <30g/L 636 
is higher than 12% [15] and 41% [12] for the total samples in other studies. We acknowledge, firstly, 637 
that discharge weight was not measured on a set day post-graft. However, time to discharge was similar 638 
in both groups and hence time of discharge weights should be comparable. Secondly, heights were 639 
missing on discharge so BMI could not be reported. Thirdly, weight and albumin are crude markers of 640 
nutritional status. Weight can be artificially elevated by PN promoting water retention [38], and 641 
hypoalbuminaemia can be attributed to catabolism, fluid redistribution, protein losing enteropathy [39], 642 
and an acute phase response to infections [40].  643 
No differences were found between gastrostomy and non-gastrostomy, or subgroups, on any post-644 
transplantation outcomes, except the EN only subgroup had a significantly shorter admission than the 645 
EN+PN subgroup. Similar subgroup analyses have also found shorter admissions [12], but also less 646 
grade III-IV aGvHD, gut aGvHD and faster platelet engraftment [13] in children maintained on EN only. 647 
The exclusion of children having a second BMT and those given first-line PN for cord bloods and 648 
gastrointestinal disorders, compromises generalisability to children transplanted with these modalities. 649 
Furthermore, children with immunodeficiency disorders formed the largest proportion in this study who 650 
are only transplanted at one other UK centre, further limiting generalisability to many children 651 
transplanted in other UK centres. However, many children in this study had diagnoses including 652 
relapsed leukaemias, and both RIC and MAC were included, thus providing evidence directly relevant 653 
to the diagnoses and conditioning regimens seen in most UK and international centres.  654 
This study has limitations, firstly the absence of randomisation and a control group who received 655 
no nutrition support. Whilst RCTs investigating prophylactic gastrostomy placement in adults have been 656 
conducted [41], there is an absence of such studies in paediatrics. Similarly, both adult and paediatric 657 
studies investigating nutrition support have lacked control groups. Both these issues are likely due to 658 
ethical considerations. Secondly, the retrospective design limited the reporting of outcomes including 659 
nutritional intakes, duration and tolerance of EN as data on these measures collected under routine 660 
clinical care, not for research purposes, was either absent or unusable. This meant we could not make 661 
correlations between these measures and outcomes reported herein. Thirdly, this study reported early 662 
outcomes, largely during admission, and cannot comment on the long-term impact of gastrostomy 663 
feeding post-discharge. Fourthly, although both groups were comparable on demographic and 664 
transplantation modalities suggesting minimal selection bias, families who chose a prophylactic 665 
gastrostomy are likely to adopt a more proactive approach to EN which may have biased findings in 666 
favour of EN with less PN use. Fifth, more gastrostomies were placed between 2014-15 (n=39) than 667 
2016-18 (n=15), which was not analytically considered, as undertaken by Seguy et al. [42]. However, 668 
nutritional and medical management remained consistent throughout this study. 669 
Whilst not limitations of this study per se, we acknowledge not reporting other issues relevant to 670 
gastrostomy feeding in BMT which were not part of the aims of this study, but could form the basis of 671 
future research. Whilst we can report no child needed their gastrostomy removed for any infectious or 672 
other complications, we have not reported the complications that arose with gastrostomies, a concern 673 
noted by others [18,19]. We intend to report the minor issues that did occur separately. Despite potential 674 
benefits of a prophylactic gastrostomy, only 10-15% annually opt for this within our centre. This study 675 
did not qualitatively explore families’ perceptions of gastrostomy feeding during BMT, an important 676 
consideration given comfort, ease of nutrition administration and image are important factors to families 677 
regarding nutrition support in this population [34]. Future qualitative studies could help identify factors, 678 
including the development of educational materials, which could be used during discussions in pre-679 
admission consultations. This will allow families to make more informed decisions regarding nutrition 680 
support prior to their child’s admission. Future studies should also prospectively investigate outcomes 681 
that could not be measured for this study, including nutritional intakes provided to the child via all 682 
nutrition support modalities, and MUAC or bioelectrical impedance as more sensitive markers of 683 
nutritional status in these children [43]. Such outcomes should be measured during admission and post-684 
discharge to allow the long-term investigation of correlations between the provision of nutrition support, 685 
the impact this has on the child’s nutritional status and, consequently, on their medical outcomes.  686 
In conclusion, this study contributes to the growing body of paediatric evidence that first-line EN is 687 
feasible in BMT and offers an innovative insight into gastrostomy feeding as an alternative method for 688 
its provision, one which may be more acceptable to older children, than traditional NGTs. Weighing the 689 
benefits against the potential risks of prophylactic gastrostomy placement in these high-risk children, 690 
whilst also accounting for patient acceptability, is a challenging decision. With few studies reporting the 691 
use of PEGs in paediatric BMT, we hope this study sparks debate around this controversial issue. 692 
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